Oculis (NASDAQ:OCS) Coverage Initiated at Lifesci Capital

Research analysts at Lifesci Capital initiated coverage on shares of Oculis (NASDAQ:OCS) in a report released on Wednesday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $55.00 price target on the stock. Lifesci Capital’s target price indicates a potential upside of 179.19% from the stock’s previous close.

A number of other research firms have also issued reports on OCS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $36.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. Chardan Capital reiterated a “buy” rating and issued a $51.00 target price on shares of Oculis in a report on Tuesday, November 11th. HC Wainwright increased their target price on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $42.33.

Oculis Price Performance

NASDAQ OCS opened at $19.70 on Wednesday. Oculis has a 12 month low of $14.00 and a 12 month high of $23.08. The firm has a market capitalization of $1.03 billion, a PE ratio of -7.82 and a beta of 0.32. The company’s 50 day simple moving average is $19.69 and its 200 day simple moving average is $18.74. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47.

Oculis (NASDAQ:OCS) last released its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The firm had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.23 million. As a group, equities research analysts forecast that Oculis will post -2.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Oculis

Several institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in shares of Oculis by 32.4% in the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock valued at $43,784,000 after purchasing an additional 563,078 shares in the last quarter. Aberdeen Group plc raised its position in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock valued at $23,847,000 after buying an additional 243,695 shares during the period. SR One Capital Management LP purchased a new stake in Oculis in the 1st quarter worth about $6,137,000. Alyeska Investment Group L.P. acquired a new stake in Oculis during the 1st quarter worth about $2,499,000. Finally, Compagnie Lombard Odier SCmA boosted its position in Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after acquiring an additional 10,000 shares during the period. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.